SMi presents the launch of Cell & Gene Therapy 2018

SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year's event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

The conference will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Expect over 16 presentations and case studies focused on the key aspects of GMP, bioprocessing, regulatory frameworks and new therapeutic developments in in the field of cell and gene.

Hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

Cell Therapy Research

Manufacturing Innovation

Global Medical Affairs

Regulatory Updates

GMP and Quality Control

Cell and Tissue Therapies (CART therapies, stem cells, cord blood, preclinical and clinical developments)

Regenerative Medicine

Advanced Therapy Production

Gene Therapy Development

Clinical Platform Development

Manufacturing

R&D of Cell and Gene Therapies

Chair for 2018

Pamela Tranter, Head of Translational Research Group, UCL

Key speakers include

Janet Glassford, Senior Quality Assessor (Biologicals), MHRA

Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon

Kei Kishimoto, Chief Scientific Officer, SelectaBiosciences

Shailesh Gupta, Senior Scientist, AstraZeneca

Peggy Sotiropoulou, R&D Manager, Research and Development, Celyad

Julie Kerby, Head of Manufacturing Development, Cell and Gene Therapy Catapult

Lior Raviv, Vice President, Development, Pluristem

Diego Aridgo, R&D Rare Disease Unit Head, Chiesi

Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotech

Emanuela Cuomo, Associate Director, Discovery Sciences, Cellular Biology Team, AstraZeneca

Yen Choo, Founder and Executive Chairman, Plasticell

Ian McKay, Innovation Lead Advanced Therapies, Innovate UK

2018 featured highlights

Discuss the challenges of accessing patients with commercial ATMPs

Understand the advantages of a risk-based approach to cell and gene therapy manufacturing

Hear the MHRA's perspective of UK and EU regulatory affairs regarding ATMPs

Explore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca

Gain insight into GMP Manufacture of plasmid DNA at the NHSBT

View the full agenda online: www.cellandgeneconference.com/wpn

Early-bird rates

Register by 31 May and save £400

Register by 29th June and save £300

Register by 31st August and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Register as Visitor to CPhI China 2018!